Early-stage – Talk Bio

Hatteras Raises $200M for Two New Funds Following HistoSonics Exit Success

4 weeks ago talkbio0Tagged Biological Science Disciplines, Early-stage, Hatteras, Hatteras Opportunity Fund I, Hatteras Venture Fund VII, HistoSonics exit, medtech, Partner in relationship, startups, venture capital

Hatteras Venture Partners; $200M; venture capital; life sciences; early-stage startups; biotech; medtech; HistoSonics exit; fundraising; Hatteras Venture Fund VII; Hatteras Opportunity Fund I

Frazier Life Sciences Raises $1.3 Billion Amid Biotech Downturn

1 month ago talkbio0Tagged biopharmaceutical startups, Early-stage, Frazier Life Sciences, Investments, oversubscribed fund, venture capital

Frazier Life Sciences; venture capital; biotech; $1.3 billion raise; early-stage investments; biopharmaceutical startups; oversubscribed fund; therapeutics

J&J CAR-T Therapy Achieves 100% Response Rate in Early-Stage Lymphoma Trial

3 months ago talkbio0Tagged CAR-T therapy, CD19 Antigens, CD20 Antigens, Clinical Trials, dual-targeting, Early-stage, Frequency of Responses, J&J, JNJ-4496, Lymphoma, Phase 1b, relapsed/refractory large-B-cell lymphoma

J&J; CAR-T therapy; lymphoma; early-stage; clinical trial; dual-targeting; CD19; CD20; objective response rate; Phase 1b; JNJ-4496; relapsed/refractory large B-cell lymphoma

Genmab Streamlines Portfolio by Cutting Early-Stage Oncology Assets

10 months ago talkbio0Tagged Early-stage, Genmab, Neoplasms, Optimization, Phase, portfolio

Genmab, oncology, early-stage candidates, portfolio optimization, Phase 3 projects

KdT Ventures Secures $100M Fourth Fund to Fuel Early-Stage Biotech Startups

11 months ago talkbio0Tagged Early-stage, frontier, Investments, KdT, Science, startups, Ventures

KdT Ventures, $100M fund, early-stage startups, biotech, frontier science, life sciences investment

Merck Halts Two Phase 3 Trials of Keytruda for Early-Stage Lung and Skin Cancers

1 year ago talkbio0Tagged Early-stage, KEYNOTE-630, KEYNOTE-867, Keytruda, Malignant neoplasm of lung, Malignant neoplasm of skin, Merck, Phase 3 trials

Merck, Keytruda, Phase 3 trials, early-stage lung cancer, skin cancer, KEYNOTE-867, KEYNOTE-630

Curie.Bio Raises $380M to Support Early-Stage Biotechs

1 year ago talkbio0Tagged accelerator, Bio, biotechs, Borisy, Curie, Early-stage, Series, venture, Weinberg, Zach

Curie.Bio, biotech accelerator, venture capital, Series A rounds, early-stage biotechs, Alexis Borisy, Zach Weinberg

Biogen Discontinues Ionis Collaboration on ALS and Angelman Syndrome Treatments Following Early Clinical Results

1 year ago talkbio0Tagged Amyotrophic Lateral Sclerosis, Angelman Syndrome, Biogen, Clinical Trials, Collaboration, Discontinuation (procedure), Early-stage, Ionis, nervous system disorder, readouts

Biogen, Ionis, ALS, Angelman Syndrome, collaboration, discontinuation, early-stage readouts, clinical trials, treatments, neurological disorders.

Biogen and Ionis Discontinue ALS Drug Development Following Unsuccessful Early Trials

1 year ago talkbio0Tagged Amyotrophic Lateral Sclerosis, Biogen, Discontinuation (procedure), Drug Development, Early-stage, Ionis, nervous system disorder, research

Biogen, Ionis, ALS, drug development, early-stage trial, disappointing results, discontinuation, neurological disorder, treatment research.

Alecensa: FDA-Approved First ALK Inhibitor for Adjuvant Treatment in Early-Stage ALK-Positive NSCLC

1 year ago talkbio0Tagged Alecensa, ALINA, ALK gene, ALK Positive, Approved, Cessation of life, disease recurrence, Early-stage, genentech, Guidelines, Immunologic Adjuvants, Inhibitor, NCCN, Non-Small Cell Lung Carcinoma, Roche (company), United States Food and Drug Administration

Alecensa, ALK Inhibitor, Adjuvant Treatment, Early-Stage ALK-Positive NSCLC, FDA Approval, Genentech, Roche Group, ALINA Study, 76% Reduction in Disease Recurrence or Death, NCCN Guidelines